Where to buy retatrutide.

You can buy retatrutide from a research-supply vendor, and nowhere else, which is the honest answer to where to buy retatrutide. No pharmacy stocks it, and no compounding pharmacy is permitted to prepare it. The only other lawful route to the genuine drug is Lilly's Phase III TRIUMPH trial.

Retatrutide

Referenced in this guide

Batch-matched COAHPLC + mass specResearch use only

The Retatrutide referenced throughout this article, supplied as a research compound with a certificate of analysis matched to the lot you receive — the check this site argues you should hold any supplier to.

Shop Retatrutide

Where can you buy retatrutide?

You can buy retatrutide from a research-supply vendor and nowhere else. Retatrutide is still an investigational drug, so no pharmacy and no compounding pharmacy may supply it. The only other lawful way a person receives the real drug is by enrolling in Lilly's Phase III TRIUMPH trial.

• A research-supply vendor. This is the only place you can buy it. Lyophilized powder under Research Use Only labeling, no prescription, and the material must stay in research use rather than going into a person.
• A clinical trial. The Phase III TRIUMPH program is enrolling. It's the only lawful way to receive the actual drug as a person, made by Lilly, with a physician watching. You can search current sites on ClinicalTrials.gov.
• A doctor's prescription. Closed. Retatrutide isn't FDA-approved, so there is nothing for a prescriber to write and no pharmacy that could fill it.
• A compounding pharmacy. Closed. The 503A route needs either FDA approval or a Drug Shortage listing for the active ingredient. Retatrutide has neither.

Which research-supply vendors to shortlist

Six vendors, ordered the way our supplier comparison orders them — on what each one will show you rather than what it claims — with every column pulled from the vendor's own storefront on 13 August 2026; there is no verified retatrutide price anywhere in that set, so pricing is benchmarked on BPC-157 across the same vendors and no price column appears here.

† Red Rock Peptides advertises that its products are verified with COAs and publishes no certificate at all, which is why it sits last rather than being left off. Stock varies by compound, so confirm a vendor actually lists retatrutide before you compare — what these columns describe is disclosure practice, and that is the part that travels across every compound a vendor sells. Disclosure: this site earns a commission on purchases made through its links, and Peptriva is one of the vendors it links to. Every column above is a document you can open or a page you can load yourself.

Retatrutide is listed under vendor codenames, and a codename is not an identity check. We hold no verified CAS number for retatrutide, so instead of a registry lookup ask for the full 39-residue sequence, an observed intact mass from the vendor's own mass-spec trace, and a lot number on the certificate that matches the vial — and treat two differently-codenamed listings as the same molecule only once all three agree.

What is retatrutide?

Retatrutide is a 39-amino-acid peptide built to hit three receptors at once: GIP, GLP-1 and glucagon. Those are the gut and pancreatic hormones that govern insulin release, appetite and energy burn.

The triple-agonist design adds glucagon receptor activation to the GIP/GLP-1 platform tirzepatide pioneered, as Jastreboff and colleagues describe.

It also carries a fatty-acid side chain. That tail helps it stick to albumin, a blood protein, which stretches the half-life far enough to allow once-weekly dosing. We'd call that the whole reason the dosing is weekly rather than daily.

The unmodified backbone weighs about 4,731 Da. With the lipid attached, the observed mass on a CoA lands in the high-4,900s. Long sequence, lipid modification, and several basic residues needing careful counterion work.

All of which puts retatrutide at the top end of synthesis difficulty for any peptide. What you pay reflects the chemistry, not vendor greed.

How do you verify retatrutide before you buy?

Four checks decide whether retatrutide is real. The vendor must name it rather than hide it behind a code. The mass-spec must cover the lipid modification. Stability data must exist. And they must be willing to say where it was made. The standard eight vendor criteria apply on top.

1. Identity transparency: no codenames, ever

Credible suppliers sell retatrutide under its actual name. Some grey-market vendors list what look like retatrutide-class compounds as FG-1, FG-2, FG-3 or FG-blend, and won't confirm the chemistry on the product page or the CoA.

Judging by price and catalog placement, these are widely believed to be GLP-1-class molecules hidden behind codes to dodge trademark and regulatory attention. If you buy one, you have no way to know what it is without paying for your own mass-spec.

Our rule: if it isn't labeled retatrutide on both the product page and the CoA, it isn't retatrutide.

2. Mass-spec must match the lipid-modified peptide

The mass on the CoA should reflect the 39-residue backbone plus the fatty acid. A report showing only the unmodified backbone points to incomplete synthesis or a substitution. On a peptide this complex, we think that one line is the most reliable authenticity check you have.

3. Storage stability documentation

The lipid tail and the basic residues make retatrutide more freeze-thaw sensitive than simpler peptides. A serious vendor documents how long the lyophilized vial holds potency at −20°C, and how long it lasts once reconstituted and refrigerated. No stability data on a peptide this complex means work got skipped.

4. Synthesis source disclosure

Ask where the peptide was made. A reputable supplier will tell you: in-house, a contract lab, or a named overseas manufacturer. It matters more here than elsewhere, because Lilly holds active patents. A source that won't name its facility may be using channels that leave you with legal exposure or quality you can't check.

What does retatrutide cost in 2026?

Retatrutide costs $200–$400 per 10 mg vial in 2026, which works out to $20–$40 per mg. That's roughly ten times what a simple 15-residue peptide costs, and the gap is chemistry rather than markup. Here's the full size-by-size map.

• 5 mg vial: $120–$220 ($24–$44/mg).
• 10 mg vial: $200–$400 ($20–$40/mg). Most common size.
• 20 mg vial: $360–$720. Slight per-mg discount over the 10 mg.
• Multi-vial discounts: 10–25% off for 3-pack or 6-pack purchases.

Below $150 per 10 mg vial, check the identity before you buy. The synthesis floor is real: a 39-residue lipid-modified peptide costs roughly 10x what an unmodified 15-residue peptide like BPC-157 costs to make.

A vendor selling it at $80–$100 per 10 mg is eating an unsustainable loss, shipping a less-pure preparation, or shipping a different compound. Only a mass-spec CoA tells you which.

Is retatrutide legal to buy?

Retatrutide is legal to buy in the US as a Research Use Only reference compound, and illegal to sell for human consumption. As of May 2026, retatrutide sits in Phase III. TRIUMPH is enrolling, and there's no FDA or EMA approval. Three things follow.

• Research-compound sales are legal. Retatrutide can ship in the U.S. as a Research Use Only reference compound. Use must stay consistent with research intent.
• Therapeutic sales are illegal. Marketing retatrutide for obesity, with dosing instructions or clinical claims, crosses into FDA jurisdiction. Credible suppliers avoid this.
• Patents are active. Eli Lilly holds the IP on LY3437943. The grey-market synthesis landscape is unsettled. The picture could shift as Phase III completes.

What are the red flags when buying retatrutide?

Six things would stop us buying a retatrutide vial. The first one, a codename in place of the compound name, is close to disqualifying on its own.

• Sold under codenames (FG-series or similar) without chemical identity disclosure. The biggest retatrutide-specific red flag.
• Pricing below $150 per 10 mg vial. Below the synthesis cost floor. Question the identity.
• Mass-spec CoA missing or showing only the unmodified backbone. The lipid modification is essential. Confirmation has to cover the modified molecule.
• Therapeutic dosing instructions on the product page. “Start at 1 mg weekly, titrate to 12 mg” is selling-for-human-use language. The FDA notices.
• No third-party ISO 17025 lab partner. Internal QC isn’t enough for a peptide this complex.
• Inconsistent or absent lot numbering. Each batch should have its own lot number, its own CoA, and its own retest date.

Retatrutide

10 mg ≥99% pure Lyophilized

39-residue triple incretin agonist with fatty-acid modification. The same reference compound cited across the Jastreboff et al. Phase II trial. Lot-specific CoA with ISO 17025 third-party HPLC and mass-spec identity ships with every order.

Learn more

Frequently asked questions

Is retatrutide legal to buy in the USA?

Yes, as a research reference compound. TRIUMPH is still running and there's no approval yet. Selling it for human consumption is illegal. Buying it from a vendor that labels and ships it Research Use Only isn't.

How much should third-party tested retatrutide cost?

You'll pay $200–$400 per 10 mg vial in 2026, which is $20–$40 per mg. Below $150 per 10 mg, verify the identity. The synthesis cost floor is real.

What is the FG-series and why does it matter?

Some grey-market vendors sell compounds as "FG-1," "FG-2" or "FG-blend" and disclose no chemistry at all. Judging by price and catalog placement, these are widely believed to be retatrutide-class molecules hidden behind codes.

Without your own mass-spec, you can't verify any of it. A credible vendor lists the compound under its real name with a clear CoA.

What should a retatrutide Certificate of Analysis show?

HPLC purity ≥98% with the chromatogram attached. A mass-spec identity matching the lipid-modified peptide, not the bare ~4,731 Da backbone. Water content by Karl Fischer titration. Counterion content. An ISO 17025-accredited lab named on the report.

Why is retatrutide so much more expensive than BPC-157 or GHK-Cu?

Retatrutide is 39 residues with a fatty-acid modification. BPC-157 is 15 residues, unmodified. GHK-Cu is 3. Every extra amino acid adds a coupling step and more purification, and the modification adds specialized chemistry on top.

That's roughly 13x the synthesis complexity, which is why you pay $40–$80/mg for a GLP-1-class peptide and $0.50–$2/mg for a dermal one.

How does retatrutide compare to tirzepatide for research?

Both are incretin agonists, but only one is approved. Tirzepatide is a dual GIP/GLP-1 agonist sold as Mounjaro and Zepbound, and SURMOUNT-1 reported 22.5% mean weight reduction at its highest dose.

Retatrutide adds glucagon receptor agonism, and its Phase II trial reported 24.2%. Our retatrutide vs tirzepatide piece runs the head-to-head.